Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone Palmitate in Schizophrenia with Acute Symptoms
NCT01685931Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2012
- Primary completion
- Dec 2014
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of paliperidone palmitate in schizophrenia, sponsored by Janssen Pharmaceutical. Started Nov 2012; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01685931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01685931.